中文 | English
Return
Total: 194 , 1/20
Show Home Prev Next End page: GO
Author:(Zhen SHANG)

1.Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs.

Boyang SHANG ; Yue SHANG ; Yongsu ZHEN ; Shuzhen CHEN

Acta Pharmaceutica Sinica 2011;46(11):1321-5

2.Anticancer Effects of the Single-chain Fv Fragment scFv (3G11) Against Type Ⅳ Collagenase in Combination with Cisplatin

Qingfang MIAO ; Boyang SHANG ; Yongsu ZHEN

Journal of Medical Research 2006;0(03):-

5.Silver nanoparticles and anti-bacterial silver coating:research and development

Lianchun XU ; Jian SHANG ; Ye SUN ; Xinguang HAN ; Zhen LIU

Chinese Journal of Tissue Engineering Research 2016;20(25):3793-3800

6.Effects of Shuangshen Ningxin capsule on ventricular remodeling and wall motion in myocardial ischemic miniature swine induced by thrombus

Zhen YU ; Jianxun LIU ; Xinzhi LI ; Xiaohong SHANG ; Lifang YAO

Chinese Pharmacological Bulletin 1987;0(02):-

7.Fetal echocardiography for diagnosis of coronary artery fistula

Zhen, XIAO ; Ning, SHANG ; Xiaoyan, MA ; Yanxia, GUO ; Chunyan, OUYANG

Chinese Journal of Medical Ultrasound (Electronic Edition) 2015;(1):46-49

8.Treatment scheme selection strategy and progress of elderly femoral neck fracture of Garden type II

Baitong LI ; Tianyi ZHOU ; Zhen LIU ; Jian SHANG

Chinese Journal of Tissue Engineering Research 2017;21(3):445-449

9.Ethical Investigations and Considerations of Clinical Trials of TCM in Diabetic Nephropathy Management

Zhen WANG ; Jianwei SHANG ; Jinzhou TIAN ; Hongfang LIU

World Science and Technology-Modernization of Traditional Chinese Medicine 2013;(4):739-742

10.Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs.

Bo-yang SHANG ; Yue SHANG ; Yong-su ZHEN ; Shu-zhen CHEN

Acta Pharmaceutica Sinica 2011;46(11):1321-1325

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 194 , 1/20 Show Home Prev Next End page: GO